RE:Next couple months could be very exciting for shareholders FDA, DEA, NIH, LABS and global pharma partner have already done this in the U.S......Libby Study, Keck School of Medicine, University of Southern California....see in green below.
The comprehensive study lays out growing evidence supporting the efficacy of cannabis in treating a wide range of conditions, from chronic pain to epilepsy and even certain types of cancer. The report also highlights the intensifying global R&D efforts aimed at unearthing the full spectrum of cannabis’ therapeutic properties. The recommendation for rescheduling cannabis in the U.S. not only broadens its patient accessibility but also catalyses the scope for more robust clinical research. Pharma companies could benefit from less restrictive regulations on clinical trials, thereby accelerating the pace of bringing cannabis-based medications to market. Moreover, rescheduling would also open the door to federal funding for cannabis research, thus mitigating some of the financial risks involved.